Lithium in migraine and cluster headache: a review1 R C Peatfield MRCP Princess Margaret Migraine Clinic Charing Cross Hospital, London W6 8RF Lithium has been used clinically for over 100 years, first, because lithium urate is very soluble, as a treatment for gout, and later as a salt substitute. It is, however, only since Cade's observation (1949) of its value in the treatment of acute episodes of mania that it has been widely and now almost exclusively used in psychiatry. There is now abundant evidence of its efficacy both in the treatment and prevention of acute mania (Coppen et al. 1971) , and the drug also seems to be valuable in the prophylaxis of recurrent depressive and manic depressive (bipolar) illness. Benefit is minimal in schizophrenia, but it has been of value in personality disorders associated with aggression or alcoholism (for review see Gerbino et al. 1978) . Serum levels of 0.6 to 1.2 mmol/l 12 hours after the last dose are considered to be a satisfactory therapeutic range, requiring an oral dosage of 600 to 1500 mg of lithium carbonate daily.
It was the similarity between the cyclical patterns of manic depression and cluster headache that first led Ekbom (1977) to suggest the use of lithium in the prophylaxis of cluster headache.
Differential diagnosis of vascular headaches
During 1980, 923 new patients complaining of headache were seen in the Princess Margaret Migraine Clinic at Charing Cross Hospital. Of these, approximately 75%O had attacks of headache fulfilling the criteria for migraine of Vahlquist (1955) , and about 500 were diagnosed as cluster headache. These syndromes can usually be distinguished clearly on clinical grounds alone (Table 1) , though it is certainly possible to have even untreated patients with features of both illnesses (Medina & Diamond 1977) . The two types of headache also appear to be biochemically distinct. The fall in platelet 5hydroxytryptamine levels during attacks of migraine (Anthony et al. 1967) does not take place during attacks of cluster headache (Anthony & Lance 1971) , and the rise in plasma histamine that has been recorded in cluster headache does not occur during attacks of migraine (Anthony & Lance 1971) . Several groups of workers have demonstrated that platelet monoamine oxidase (MAO) is lower both in migraine and cluster headache (Bussone et al 1977 , Glover et al. 1977 ; preliminary results from our group suggest that the activity of phenolsulphotransferase (an enzyme found in the platelet cytosol) is reduced in migraine, but not in cluster headache (Figure 1 ). Platelet succinate dihydrogenase activity is also low both in migraine and cluster headache, but it does not correlate with monoamine oxidase activity.
Treatment of cluster headache
The episodes of pain are too severe and too short-lived for any non-addictive analgesic to be of value if it is taken as the pain starts. Management has to concentrate on regular treatment taken in an attempt to suppress the pain. Unfortunately the condition is too uncommon for every treatment regimen to have been subjected to a double blind trial. Symonds (1956) first described the use of regular ergotamine injections during the cluster and, despite the absence of any controlled data, this has been the standard treatment against which all others have to be judged. Unfortunately ergotamine injection is no longer available, and plasma ergotamine levels do not seem quite so high after administration by any other route (Ala-Hurula et al. 1979) . Oral prednisone has been shown to be effective, even when taken in a single 30 mg dose, to judge from one of the few double blind controlled trials in the literature (Jammes 1975) . Russell (1979) has shown that treatment with combined chlorpheniramine and cimetidine is ineffective, whilst Caviness & O'Brien (1980) have found some improvement with chlorpromazine, in a small open study.
Lithium therapy has not been subjected to a double blind trial. Since Ekbom's original description (see Ekbom 1977) , several open studies have been published. Kudrow (1978) compared methysergide, prednisone and lithium in both episodic and chronic cluster headache patients in an open trial. His results are shown in Table 2 . The long-term toxicity of both methysergide and prednisone has led to lithium being used at first only for chronic migrainous neuralgia (Pearce 1980 ), but Mathew (1978) has described 31 patients, 14 with the episodic and 17 with the chronic form: 80% of the former and 84% of the latter group showed a definite improvement within 2 weeks, a little faster than the response in mania (Gerbino et al. 1978) . The lithium had to be stopped in only one patient, beacuse of disabling lethargy.
Between January and December 1980, 48 patients with cluster headache were seen in the Princess Margaret Migraine Clinic at Charing Cross Hospital. Of these 9 were women and 4 had had unremittant headaches for 3 months or longer. Of the 48 patients, 8 were quiescent when first seen and 4 were expected to settle within a few days and so were given ergotamine or corticosteroids. Two patients had atypical headaches and 3 lived too far away for adequate follow up. The remaining 31 were given lithium carbonate (Priadel initially 800 mg at night). Fourteen patients showed a marked improvement in the first week, having no attacks or no more than a single mild one; 10 patients showed a lesser improvement, with one severe attack or several mild ones during the week. The mean lithium levels in these 2 groups after 7 days treatment were 0.69 and 0.60 mmol/l respectively, and these were not significantly different (Student's t test). One patient showed a smaller improvement and one did not attend for follow up. Five patients did not improve significantly on this dosein 2 cases intractable vomiting was induced and in 3 cases a larger dose of lithium (up to 1600 mg) was needed to control the headaches. We are planning a controlled trial of this treatment.
Treatment of migraine
A wide variety of drugs are effective in the prevention of attacks of migrainous headaches (for review see Peatfield & Rose 1981a) . The most useful of these are propranolol and pizotifen, which have very little effect in cluster headache. By contrast, corticosteroids are of no value in migraine. Ergotamine is the only drug useful in both conditions, though it tends to be employed for the treatment of established migrainous headaches rather than their prevention.
We have recently studied the effect of lithium treatment in common and classical migraine (Peatfield & Rose 1981b) . Three of Kudrow's patients with cluster headache developed a prolonged throbbing occipital headache while on lithium treatment (Kudrow 1977) . There have, however, been some reports that lithium may reduce the frequency and severity of attacks (Nieper 1973 , Chazot et al. 1979 ). Medina & Diamond (1981) have found it of value in those cases of migraine which follow a cyclical pattern.
In a small open trial we gave lithium carbonate, again 800 mg at night, to 2 patients with classical migraine and 3 with common migraine (Peatfield & Rose 1981b) . In all 5 cases the patients' headaches became very much worse and 3 refused to continue the trial after 21, 10 and 7 days respectively. One of the patients with a history of common migraine had her first ever attack of classical migraine during the trial. In one case the treatment was continued for 6 weeks without benefit. Two of our cluster headache patients have shown migrainous features during lithium treatment. One man had a left hemianopia lasting one hour followed by nausea and a rightsided headache, with no previous history of such experiences; and another developed a sensitivity to chocolate, only during the treatment.
Lithium, therefore, seems to exacerbate common and classical migraine, and may induce features of these in cluster headache patients. This finding suggests that there may be fundamental differences in the pathophysiology of the two conditions.
Mode of action of lithium
It is unfortunate that the mode of action of lithium, even in psychiatry, is so poorly understood. The drug seems to affect a wide variety of biochemical systems, but in many experimental studies the concentrations used have been very different from those effective in psychiatry or neurology, and in many cases they are incompatible with life. There also seems to be a difference between the short-term effect of lithium added in vitro and the in vivo effects of chronic lithium administration. Improvement in mania usually takes several days (Gerbino et al. 1978 ), suggesting that any acute actions of lithium noted only in vitro are probably of little consequence.
Long-term studies of psychiatric patients are necessarily confined to constituents of blood. The analogies between the red cell membrane and those in the brain, and between platelets and synaptosomes may not be wholly valid. The following studies are of possible relevance.
(1) There is some evidence of depressed sodium/potassium pump activity in red cells in mania (Hokin-Neaverson et al. 1974), and Naylor et al. (1974) have shown that this was reversed by chronic lithium administration. Lithium treatment also increases ATPase activity in erythrocytes (Hesketh 1976 ).
(2) The rate of 5-hydroxytryptamine (5HT) uptake into platelets is reduced in depression, both during the illness and after recovery. Uptake of this monoamine returns to normal after 6 weeks' lithium treatment (Coppen et al. 1980) , though this effect is not seen after only 3 weeks' treatment (Arora & Meltzer 1980) , and lithium added in vitro has the opposite effect, reducing uptake (Coppen et al. 1980) . Coppen et al. (1979) have recently shown that platelet 5HT uptake is reduced in migraine. There have been no studies of platelet physiology in cluster headache. Cerebral 5HT turnover in the rat is increased by lithium (Perez-Cruet et al. 1971) .
(3) Platelet MAO activity is reduced in manic depression (Mann 1979 , Reveley et al. 1981 ) but is increased in unipolar depression (Reveley et al. 1981) . Some workers have suggested that MAO activity is increased by lithium treatment in both cases (Bockar et al 1974 , Mann 1979 , but this finding could not be repeated by Berrettini et al. (1979 ), or Reveley et al. (1981 . This may be due to the different substrates used to measure MAO, to contamination with plasma oxidases, or to pairs of samples not being assayed simultaneously (Reveley et al. 1981) . The widely different MAO levels in unipolar and bipolar psychiatric illnesses contrast with the favourable response of both to lithium, suggesting that the effect of lithium on monoamine oxidase, if any, is not relevant; indeed Sullivan et al. (1977) suggested that lithium responsiveness in manic depression is associated with normal MAO levels. In our more recent study of migraine patients we have again failed to correlate the levels of MAO with a history of headaches precipitated by amine-containing foods such as cheese, thus casting doubt on the pathophysiological significance of the monoamine oxidase levels in any case. Dawood & Welch (1979) have shown that lithium increases MAO activity in rat brain cells by 40%.
(4) Platelet aggregability is increased in migraine (see Couch & Hassanein 1977) , and there is evidence that the platelet-release reaction takes place during headaches (Gawel et al. 1979 ). Lithium will enhance platelet aggregation in vitro (Imandt et al. 1977) . Decreased platelet cyclic AMP levels are associated with aggregation and release reaction (Moncada & Vane 1978) , and Paul et al. (1971) have found increased urinary excretion of cyclic AMP in mania. Lithium enhances stimulation of adenyl cyclase by adrenaline (Ebstein et al. 1976) or by prostaglandin El (Wang et al. 1974 ).
(5) Karmazyn et al. (1978) have suggested that lithium interferes with the release of prostaglandins, at least in response to vasopressin.
Conclusions
The study of vascular headaches is still at a stage when the pathophysiology is explored indirectly by working backwards from the observed effects of drug trials. Unfortunately, as with corticosteroids, the pharmacology of lithium is so complex that more heat than light has been generated so far. Nevertheless, there seems little doubt that the diametrically-opposed effect of lithium in migraine and cluster headache provides further evidence that there are fundamental distinctions between the two conditions.
